Modality
siRNA
MOA
GLP-1/GIP
Target
CD123
Pathway
Incretin
Urothelial Ca
Development Pipeline
Preclinical
~Jan 2020
→ ~Apr 2021
Phase 1
~Jul 2021
→ ~Oct 2022
Phase 2
Jan 2023
→ Jul 2025
Phase 2Current
NCT05936888
2,618 pts·Urothelial Ca
2023-01→2025-07·Recruiting
NCT03229530
490 pts·Urothelial Ca
2025-05→TBD·Recruiting
3,108 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-129mo agoPh2 Data· Urothelial Ca
2025-07-149mo agoConference· Urothelial Ca
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3
P2
Recruit…
P2
Recruit…
Catalysts
Ph2 Data
2025-07-12 · 9mo ago
Urothelial Ca
Conference
2025-07-14 · 9mo ago
Urothelial Ca
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05936888 | Phase 2 | Urothelial Ca | Recruiting | 2618 | VA |
| NCT03229530 | Phase 2 | Urothelial Ca | Recruiting | 490 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 | |
| Zorizumab | Beam | Approved | CD123 | |
| BEA-4274 | Beam | Phase 1/2 | ALK | |
| Adagralucimab | Caribou Bio | NDA/BLA | CD123 | |
| PST-2276 | Poseida | Approved | Aβ |